Benjamine Liu

Benjamine Liu, Ph.D. is the chief executive officer and co‑founder of Formation Bio, an AI‑native pharmaceutical company redefining how new medicines are developed and brought to patients. Formation Bio leverages advanced technology, data science, and artificial intelligence to optimize clinical development — accelerating trial design, execution, and drug advancement with the goal of significantly reducing the time and cost typically required to deliver treatments to patients.

Liu has a distinguished academic background in computational biology. He holds a Doctor of Philosophy (D.Phil.) from the University of Oxford, where he was a Rhodes Scholar, a Master of Philosophy (MPhil) in computational biology from the University of Cambridge, and a Bachelor of Science in biology from Yale University. His doctoral research combined machine learning and large‑scale biomedical data to inform diagnostics and therapeutic strategies, and it inspired his focus on solving the clinical trial bottleneck in drug development.

Under Liu’s leadership, Formation Bio has forged innovative collaborations — including AI partnerships with organizations such as OpenAI and Sanofi — and introduced AI‑driven tools like Muse to streamline patient recruitment and other clinical processes. The company has secured significant funding to expand its proprietary pipeline and drug development platform, underscoring its mission to bring transformative treatments to patients faster and more efficiently.

Liu’s vision centers on integrating technology with the complexities of biopharmaceutical innovation, enabling smaller biotechs and large pharma partners to advance more clinical programs and address unmet medical needs globally.